首页 › 基金 › Vestal Point Capital, LP › ELVN
Vestal Point Capital, LP 对 ELVN 的持仓历史
ENLIVEN THERAPEUTICS INC · 医疗保健
Vestal Point Capital, LP 在 Q3 2026 的 13F 申报中披露持有 ELVN(ENLIVEN THERAPEUTICS INC)3,225,000 股,市值约 US$147.8M,约占其申报组合的 3.82%,在其申报持仓中市值排名第 10 位。 Vestal Point Capital, LP 最近 6 个申报季度中有 6 个季度披露了 ELVN 持仓,最早可追溯至 Q2 2025。
最后更新: 2026-11-17 · 来源: SEC EDGAR Form 13F-HR
Vestal Point Capital, LP 对 ELVN 的持仓演变
Vestal Point Capital, LP 于 Q2 2025 首次披露 ELVN 持仓:250,000 股(约 US$5.0M)。 该持仓在 Q2 2026 达到峰值 4,000,000 股,市值约 US$203.0M。 在 6 次申报中,Vestal Point Capital, LP 3 次增持、2 次减持、0 次保持不变。 最近一期申报(Q3 2026)显示持股 3,225,000 股、市值约 US$147.8M,环比减持 -775,000 股。。 持仓曾出现大幅变动:Q3 2025 增持约 364% (随后一个季度股价下跌 25%)、Q4 2025 增持约 230% (随后一个季度股价上涨 155%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q2 2025 | 250.00K | $5.01M | 新进 |
| Q3 2025 | 1.16M | $23.75M | 增持 |
| Q4 2025 | 3.83M | $58.98M | 增持 |
| Q1 2026 | 3.25M | $127.40M | 减持 |
| Q2 2026 | 4.00M | $203.00M | 增持 |
| Q3 2026 | 3.23M | $147.83M | 减持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 ELVN 与 13F 数据
ELVN(ENLIVEN THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 56 只申报持有 ELVN,申报仓位最大的包括:ORBIMED ADVISORS LLC (US$310.6M), Polar Capital Holdings Plc (US$294.5M), Commodore Capital LP (US$150.1M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 ELVN 的基金
- ORBIMED ADVISORS LLC 6.78M 股 · $310.64M · Q3 2026
- Polar Capital Holdings Plc 6.43M 股 · $294.53M · Q3 2026
- Commodore Capital LP 3.27M 股 · $150.13M · Q3 2026
- Fairmount Funds Management LLC 1.86M 股 · $85.06M · Q3 2026
- Siren, L.L.C. 1.48M 股 · $67.62M · Q3 2026
- Bellevue Group AG 1.47M 股 · $67.34M · Q3 2026
- Logos Global Management LP 1.08M 股 · $49.51M · Q3 2026
- First Light Asset Management, LLC 1.02M 股 · $46.68M · Q3 2026
- Novo Holdings A/S 1.00M 股 · $45.84M · Q3 2026
- First Turn Management, LLC 958.70K 股 · $43.95M · Q3 2026
- SAMLYN CAPITAL, LLC 936.17K 股 · $42.91M · Q3 2026
- BAKER BROS. ADVISORS LP 905.19K 股 · $41.49M · Q3 2026
更多关于 Vestal Point Capital, LP
常见问题
How long has Vestal Point Capital, LP held ELVN?
Vestal Point Capital, LP has disclosed ELVN holdings in 6 of the last 6 reported quarters, going back to Q2 2025.
What is Vestal Point Capital, LP's current position in ELVN?
As of Q3 2026, Vestal Point Capital, LP holds 3.23M shares of ELVN (ENLIVEN THERAPEUTICS INC), valued at $147.83M, representing 3.82% of its reported portfolio and ranking #10.
Has Vestal Point Capital, LP been buying or selling ELVN?
In the latest 13F filing (Q3 2026), Vestal Point Capital, LP reduced its position in ELVN. The position peaked in Q2 2026 at 4.00M shares.
Which other funds hold ELVN?
Other major institutional holders of ELVN include ORBIMED ADVISORS LLC, Polar Capital Holdings Plc, Commodore Capital LP, among 56 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.